Haleon (HLN) Stock Price, News & Analysis

Company Overview

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands. It also offers various over-the-counter products comprising nasal drops, and cold, flu, and allergy relief products under Otrivine, Theraflu, and Flonase brands for respiratory issues; anti-inflammatory and pain relief products under Voltaren, Panadol, and Advil brands; and antacids and antihistamine products under TUMS, ENO, and Fenistil brands for digestive health and other issues. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was founded in 1715 and is headquartered in Weybridge, the United Kingdom.

Key Stats

• Today's Range: $10.53 to $10.70
• 50-Day Range: $9.28 to $10.77
• 52-Week Range: $8.25 to $10.85
• Volume: 20.04 million shs
• Average Volume: 7.98 million shs
• Market Capitalization: $48.15 billion
• P/E Ratio: 31.40
• Dividend Yield: 2.15%
• Price Target: $11.25
• Consensus Rating: Moderate Buy

Haleon Stock Analysis - MarketRank™

Haleon scored higher than 47% of companies evaluated by MarketBeat, and ranked 614th out of 924 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Haleon has received a consensus rating of Moderate Buy. The company's average rating score is 2.56, and is based on 3 buy ratings, 5 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Haleon has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: 13.95%

Earnings Growth

Earnings for Haleon are expected to grow by 13.95% in the coming year, from $0.43 to $0.49 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Haleon is 31.40, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 22.58.

Price to Earnings Ratio vs. Sector

The P/E ratio of Haleon is 31.40, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 26.45.

Price to Earnings Growth Ratio

Haleon has a PEG Ratio of 2.82. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Haleon has a P/B Ratio of 2.37. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.50% of the float of Haleon has been sold short.

Short Interest Ratio / Days to Cover

Haleon has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Haleon has recently increased by 25.11%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 2.5 / 5
• Dividend Strength: Moderate

Dividend Yield

Haleon pays a meaningful dividend of 2.21%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

Haleon does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Haleon is 58.97%. This payout ratio is at a healthy, sustainable level, below 75%.

Dividend Sustainability

Based on earnings estimates, Haleon will have a dividend payout ratio of 46.94% next year. This indicates that Haleon will be able to sustain or increase its dividend.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.50% of the float of Haleon has been sold short.

Short Interest Ratio / Days to Cover

Haleon has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Haleon has recently increased by 25.11%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 3.3 / 5
• News Sentiment: 0.99

News Sentiment

Haleon has a news sentiment score of 0.99. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.80 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 22 news articles for Haleon this week, compared to 6 articles on an average week.

Search Interest

Only 1 people have searched for HLN on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.

MarketBeat Follows

5 people have added Haleon to their MarketBeat watchlist in the last 30 days. This is an increase of 25% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Haleon insiders have not sold or bought any company stock.

Percentage Held by Institutions

Only 6.67% of the stock of Haleon is held by institutions.

HLN Stock Analysis - Frequently Asked Questions

How have HLN shares performed this year?

Haleon's stock was trading at $9.54 at the beginning of the year. Since then, HLN shares have increased by 11.9% and is now trading at $10.6750.
View the best growth stocks for 2025 here.

How were Haleon's earnings last quarter?

Haleon plc (NYSE:HLN) released its earnings results on Thursday, February, 27th. The company reported $0.05 earnings per share (EPS) for the quarter. The company earned $3.54 billion during the quarter, compared to analyst estimates of $3.38 billion. Haleon had a net margin of 10.85% and a trailing twelve-month return on equity of 14.76%.
Read the conference call transcript.

Who are Haleon's major shareholders?

Haleon's top institutional investors include Dodge & Cox (3.75%), Wellington Management Group LLP (0.41%), Douglas Lane & Associates LLC (0.19%) and Envestnet Asset Management Inc. (0.16%).

How do I buy shares of Haleon?

Shares of HLN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Haleon own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Haleon investors own include Waste Connections (WCN), American Water Works (AWK), The RMR Group (RMR), AUO (AUOTY), DiamondRock Hospitality (DRH), iShares Micro-Cap ETF (IWC) and Triple Flag Precious Metals (TFPM).

Company Calendar

• Last Earnings: 2/27/2025
• Record date for 6/5 Dividend: 4/25/2025
• Ex-Dividend for 6/5 Dividend: 4/25/2025
• Today: 5/15/2025
• Next Earnings (Estimated): 5/21/2025
• Dividend Payable: 6/05/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Toilet preparations
• Sub-Industry: Consumer Goods
• Current Symbol: NYSE:HLN
• CIK: 1900304
• Web: www.haleon.com
• Phone: 44-19-3282-2000
• Fax: N/A
• Employees: 25,408
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $11.25
• High Stock Price Target: $11.25
• Low Stock Price Target: $11.25
• Potential Upside/Downside: +6.1%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.56
• Research Coverage: 9 Analysts

Profitability

• EPS (Most Recent Fiscal Year): $0.39
• Trailing P/E Ratio: 31.16
• Forward P/E Ratio: 24.66
• P/E Growth: 2.82
• Net Income: $1.30 billion
• Net Margins: 10.85%
• Pretax Margin: N/A
• Return on Equity: 14.76%
• Return on Assets: 7.32%

Debt

• Debt-to-Equity Ratio: 0.44
• Current Ratio: 0.84
• Quick Ratio: 0.58

Sales & Book Value

• Annual Sales: $11.23 billion
• Price / Sales: 4.26
• Cash Flow: $0.39 per share
• Price / Cash Flow: 27.07
• Book Value: $4.51 per share
• Price / Book: 2.35

Miscellaneous

• Outstanding Shares: 4,510,190,000
• Free Float: N/A
• Market Cap: $47.83 billion
• Optionable: Not Optionable
• Beta: 0.24